{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:10:02Z","timestamp":1791943802929,"version":"4.3.4"},"reference-count":43,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2026,2,27]]},"published-print":{"date-parts":[[2026,7]]},"DOI":"10.2967\/jnumed.125.271859","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:15:16Z","timestamp":1774541716000},"page":"1102-1108","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Value of Early Follow-Up PSMA PET\/CT After 2 Cycles of [\n                    <sup>177<\/sup>\n                    Lu]Lu-PSMA RPT in Patients with mCRPC: Comparison with PSA Dynamics"],"prefix":"10.2967","volume":"67","author":[{"given":"Liam","family":"Widjaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hornfeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie C.","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz J.","family":"Gildehaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Klimek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026070106450745000_67.7.1102.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026070106450745000_67.7.1102.2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"key":"2026070106450745000_67.7.1102.3","unstructured":"FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. Food and Drug Administration website. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication. Accessed June 17, 2025."},{"key":"2026070106450745000_67.7.1102.4","unstructured":"Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. Novartis website. https:\/\/www.novartis.com\/news\/media-releases\/novartis-pluvictotm-demonstrates-statistically-significant-and-clinically-meaningful-rpfs-benefit-patients-psma-positive-metastatic-hormone-sensitive-prostate-cancer. Published June 2, 2025."},{"key":"2026070106450745000_67.7.1102.5","doi-asserted-by":"crossref","first-page":"e222148","DOI":"10.1148\/radiol.222148","article-title":"Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer","volume":"308","author":"Gafita","year":"2023","journal-title":"Radiology."},{"key":"2026070106450745000_67.7.1102.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2026070106450745000_67.7.1102.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2026070106450745000_67.7.1102.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2026070106450745000_67.7.1102.9","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.3390\/cancers13122938","article-title":"PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under 177Lu-PSMA-617 radioligand therapy","volume":"13","author":"Widjaja","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2026070106450745000_67.7.1102.10","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","article-title":"PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis","volume":"48","author":"Seifert","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.11","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.7150\/thno.47251","article-title":"Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy","volume":"10","author":"Seifert","year":"2020","journal-title":"Theranostics."},{"key":"2026070106450745000_67.7.1102.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.240242"},{"key":"2026070106450745000_67.7.1102.13","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1007\/s00259-025-07319-7","article-title":"[99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer","volume":"52","author":"Kunte","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40658-023-00529-8","article-title":"Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT\/CT acquisition","volume":"10","author":"Resch","year":"2023","journal-title":"EJNMMI Phys."},{"key":"2026070106450745000_67.7.1102.15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/cancers17142313","article-title":"Feasibility of automated image-based red bone marrow dosimetry for [177Lu]Lu-PSMA radiopharmaceutical therapy of metastatic castration-resistant prostate cancer","volume":"17","author":"Rumiantcev","year":"2025","journal-title":"Cancers (Basel)."},{"key":"2026070106450745000_67.7.1102.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269431"},{"key":"2026070106450745000_67.7.1102.17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13550-025-01211-z","article-title":"RECIP 1.0 + PSA for response assessment in mCRPC patients treated with 225Ac\/177Lu PSMA combination therapy","volume":"15","author":"Sheikh","year":"2025","journal-title":"EJNMMI Res."},{"key":"2026070106450745000_67.7.1102.18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00259-025-07632-1","article-title":"Refining the clinical utility of [177Lu]Lu\/[225Ac]Ac-PSMA tandem RLT in patients with metastatic castration resistant prostate cancer","volume":"53","author":"Widjaja","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.251017"},{"key":"2026070106450745000_67.7.1102.20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/biomedicines10050946","article-title":"Total tumor volume on 18F-PSMA-1007 PET as additional imaging biomarker in mCRPC patients undergoing PSMA-targeted alpha therapy with 225Ac-PSMA-I&T","volume":"10","author":"Unterrainer","year":"2022","journal-title":"Biomedicines."},{"key":"2026070106450745000_67.7.1102.21","doi-asserted-by":"crossref","first-page":"663631","DOI":"10.3389\/fonc.2021.663631","article-title":"Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET\/CT imaging in prostate cancer patients","volume":"11","author":"Mittlmeier","year":"2021","journal-title":"Front Oncol."},{"key":"2026070106450745000_67.7.1102.22","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0664"},{"key":"2026070106450745000_67.7.1102.23","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1007\/s00259-022-05910-w","article-title":"mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193581"},{"key":"2026070106450745000_67.7.1102.25","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2026070106450745000_67.7.1102.26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2026070106450745000_67.7.1102.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452"},{"key":"2026070106450745000_67.7.1102.28","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224055"},{"key":"2026070106450745000_67.7.1102.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.242057"},{"key":"2026070106450745000_67.7.1102.30","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s00259-024-06594-0","article-title":"The accuracy and intra- and interobserver variability of PSMA PET\/CT for the local staging of primary prostate cancer","volume":"51","author":"Donswijk","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2023.11.001","article-title":"A practical guide to the pearls and pitfalls of PSMA PET imaging","volume":"54","author":"Voter","year":"2024","journal-title":"Semin Nucl Med."},{"key":"2026070106450745000_67.7.1102.32","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","article-title":"Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria","volume":"49","author":"Gafita","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.33","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1007\/s00259-025-07323-x","article-title":"PET imaging utilization and trends in Germany: a comprehensive survey","volume":"52","author":"Holzgreve","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.semnuclmed.2024.08.003","article-title":"Total-body PET\/CT: challenges and opportunities","volume":"55","author":"Mingels","year":"2025","journal-title":"Semin Nucl Med."},{"key":"2026070106450745000_67.7.1102.35","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269319"},{"key":"2026070106450745000_67.7.1102.36","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1390-8"},{"key":"2026070106450745000_67.7.1102.37","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","article-title":"EANM practice guideline for quantitative SPECT-CT","volume":"50","author":"Dickson","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.38","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00259-025-07613-4","article-title":"[177Lu]Lu-PSMA SPECT\/CT for early response assessment using quantitative RECIP 1.0","volume":"53","author":"Kassas","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.39","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.7150\/thno.106574","article-title":"Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer\u2014 a systematic review and meta-analysis","volume":"15","author":"Ninatti","year":"2025","journal-title":"Theranostics."},{"key":"2026070106450745000_67.7.1102.40","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262713"},{"key":"2026070106450745000_67.7.1102.41","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s00259-022-05744-6","article-title":"Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2026070106450745000_67.7.1102.42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13550-024-01190-7","article-title":"Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy","volume":"15","author":"Heilinger","year":"2025","journal-title":"EJNMMI Res."},{"key":"2026070106450745000_67.7.1102.43","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.271859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:07:23Z","timestamp":1782914843000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.271859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,1]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.2967\/jnumed.125.271859"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.271859","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}